Clinical trials: Bleeding
Vitreous Hemorrhage, Diabetic Retinopathy
Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage
The purpose of this study is to determine if intravitreal injection of Vitrase (ovine hyaluronidase) clears vitreous hemorrhage
- Trial name
- NCT00198510
- Testing
- Vitrase
- Where
- 73 sites in United States, Canada and 1 more
- Volunteers
- 750 people
- Sponsor
- Bausch & Lomb Incorporated
Vascular Anomalies, Hemorrhage
Safety and Efficacy Of Amber Peripheral Liquid Embolic System
A prospective, single-arm, multicenter, open-label, First-in-Human \& Pivotal Study to assess the safety and efficacy of amber SEL-P in 70 patients requiring peripheral embolization: vascular anomalies, hemorrhages, aneurysms…
- Conditions
- Vascular Anomalies, Hemorrhage, Aneurysm, Pseudoaneurysm
- Trial name
- OPAL (NCT06456125)
- Testing
- amber SEL-P Peripheral Liquid Embolic System
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- LVD Biotech S.L
Severe Hemophilia A
Post Approval Phase 4 Study to Learn More About How Safe Octocog Alfa is, and How Well it Works in Patients With Severe Hemophilia A in India
Hemophilia A is a genetic condition that makes it hard for blood to clot properly. This happens because the body does not have enough of a protein called Factor VIII, which helps stop bleeding.
- Trial name
- HEMOCT INDIA (NCT07446010)
- Testing
- Octocog alfa
- Volunteers
- 30 people
- Sponsor
- Bayer
Brain Injuries, Traumatic
Biomarkers of Traumatic Brain Injury With Tbit System
A prospective, multi-center, non-randomized, pivotal study to assess the safety and efficacy of the Tbit™ System to aid in patient evaluation, suspected of traumatic brain injury, as adjunct companion test to radiologic standard…
- Trial name
- NCT04107662
- Testing
- Tbit system
- Volunteers
- 740 people
- Sponsor
- BioDirection Inc
Acquired Bleeding Disorder, Intracerebral Haemorrhage
Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage
This trial is conducted in Asia, Europe and Oceania. The aim of this trial is to evaluate the safety and preliminary efficacy of activated recombinant human factor VII (NovoSeven®) in preventing early haematoma growth in acute…
- Trial name
- NCT01566786
- Testing
- activated recombinant human factor VII
- Where
- 9 sites in Australia, Denmark and 7 more
- Volunteers
- 48 people
- Sponsor
- Novo Nordisk A/S
Hemophilia B
Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B
The primary objective of the study was to evaluate the safety of recombinant coagulation factor IX Fc fusion protein (rFIXFc, BIIB029) in previously untreated patients (PUPs) with severe hemophilia B.
- Trial name
- PUPs B-LONG (NCT02234310)
- Testing
- rFIXFc
- Where
- 27 sites in United States, Australia and 9 more
- Volunteers
- 33 people
- Sponsor
- Bioverativ, a Sanofi company
Purpura, Thrombocytopaenic, Idiopathic
A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.
Chronic immune thrombocytopenia (ITP) is a longterm disease in which the blood does not clot normally. This is due to a low number of blood cell fragments called platelets.
- Trial name
- NCT01440361
- Testing
- Belimumab
- Sponsor
- GlaxoSmithKline
Gingivitis
A Clinical Trial to Test the Effect of an Experimental Mouth Rinse on Gum Disease
Subjects will be given special instructions about eating, smoking and taking care of their teeth during the 18 hours before they come to the dentist's office for screening.
- Trial name
- NCT01821261
- Testing
- Mouth Rinse 19668-012, Mouth Rinse 500347078842, Toothpaste 035000513007
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Myocardial Infarction (MI)
Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical Practice
This is an observational study based on secondary data extracted from multiple register-based data sources in the US and Europe (Sweden, United Kingdom, Italy, Germany).
- Trial name
- ALETHEIA (NCT04568083)
- Where
- 6 sites in United States, Germany and 3 more
- Volunteers
- 7,035 people
- Sponsor
- AstraZeneca
Intracerebral Hemorrhage
AI ENRICH - AI Detection of ICH
To evaluate the performance of the Viz RECRUIT software in subjects identified as symptomatic of a stroke event as determined by standard of care imaging assessments and interpretation.
- Trial name
- NCT03865979
- Testing
- Viz RECRUIT
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Viz.ai, Inc.
Congenital Bleeding Disorder, Haemophilia A
Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B
This trial is conducted in Europe and Asia. The aim of this clinical trial is to investigate the safety, pharmacokinetics (how the trial drug is distributed in the body) and pharmacodynamics (physiological effects of the drug on…
- Conditions
- Congenital Bleeding Disorder, Haemophilia A, Haemophilia B, Healthy
- Trial name
- Explorer 1 (NCT01228669)
- Testing
- NNC 0172-0000-2021
- Where
- 16 sites in Austria, Denmark and 9 more
- Volunteers
- 52 people
- Sponsor
- Novo Nordisk A/S
Bleeding
ClotFoam as an Adjunct to Hemostasis in Abdominal Surgery - Liver Bleeding is Encountered
Phase 1 Single-Arm Study Evaluating ClotFoam as an Adjunct to Hemostasis in Abdominal Surgery in Which Liver Bleeding is Encountered.
- Trial name
- NCT02264730
- Testing
- ClotFoam
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Biomedica Management Corporation
Venous Thromboembolism
Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities
The study objective is to evaluate the efficacy and safety of oral YM150 for prevention of venous thromboembolism in subjects undergoing hip fracture surgery or surgery in the lower extremities.
- Trial name
- NCT00937911
- Testing
- YM150
- Where
- 8 sites in Japan
- Volunteers
- 101 people
- Sponsor
- Astellas Pharma Inc
Gingival Bleeding, Plaque Induced Gingival Disease
Comparative Study to Evaluate the Efficacy of an Alcohol-free Mouthwash Regimen With CPC+Zn, Flossing and Brushing, and an Alcohol-based Mouthwash Regimen With Essential Oils in Reducing Plaque and Gingivitis.
This is a Phase III, randomized, one-center, parallel group, double blinded, clinical study to evaluate the efficacy of an alcohol-free mouthwash containing CPC+Zn as compared to dental flossing and to rising with an essential…
- Conditions
- Gingival Bleeding, Plaque Induced Gingival Disease, Gingival Diseases, Gingivitis and Periodontal Diseases
- Trial name
- PGMWII (NCT06598072)
- Testing
- Mouthwash CPC+Zn+F, Essential oils mouthwash, Dental floss
- Where
- Mexico
- Volunteers
- 120 people
- Sponsor
- Colgate Palmolive
Coronary Disease, Drug Eluting Stent
Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Firehawk TM Stent in High Bleeding Risk Patients With Coronary Artery Disease
This study is to assess the clinical non-inferiority of 1 month (short-term) vs 6 months (long-term) of dual anti-platelet therapy in patients undergoing percutaneous intervention implanted sirolimus -eluting stent with abluminal…
- Conditions
- Coronary Disease, Drug Eluting Stent, Percutaneous Coronary Intervention, Dual Antiplatelet Therapy
- Trial name
- NCT03287167
- Testing
- 1 month DAPT, 6 months DAPT
- Where
- China
- Volunteers
- 1,720 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Venous Thromboembolism
Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban
To estimate the real-world rates of recurrent Venous thromboembolism (VTE), major bleeding and all-cause mortality in patients with Cancer-associated thrombosis (CAT) treated with rivaroxaban
- Trial name
- NCT03214172
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Bayer
Congenital Bleeding Disorder, Haemophilia A
A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A
This trial is conducted globally. The aim of the trial is to investigate safety, efficacy and pharmacokinetics (the exposure of the trial drug in the body) of NNC 0129-0000-1003 (N8-GP) in children with severe haemophilia A who…
- Trial name
- pathfinder™5 (NCT01731600)
- Testing
- turoctocog alfa pegol
- Where
- 51 sites in United States, Brazil and 14 more
- Volunteers
- 68 people
- Sponsor
- Novo Nordisk A/S
Uterine Leiomyoma
Directed Ablation of Uterine Fibroids Using a Noninvasive Approach
The purpose of this clinical study is to assess the safety and effectiveness of the Mirabilis System for treating uterine fibroids in women who are seeking relief from fibroid-related abnormal uterine bleeding but want to avoid…
- Trial name
- DIANA (NCT03219385)
- Testing
- Mirabilis System
- Volunteers
- 180 people
- Sponsor
- Mirabilis Medica, Inc.
Venous Thromboembolism
YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness
To evaluate the safety and efficacy of the oral dose of YM150 for prevention of venous thromboembolism (VTE) in patients with acute medical illness.
- Trial name
- NCT01028950
- Testing
- YM150
- Where
- 5 sites in Japan
- Volunteers
- 52 people
- Sponsor
- Astellas Pharma Inc
Heavy Menstrual Bleeding
A Study Called Champion-HMB to Learn More About Females With Heavy Menstrual Bleeding and Available Treatments to Enable Earlier Diagnosis and to Predict Courses of Treatment
This is an observational study in which patient data from the past of females with heavy menstrual bleeding (HMB) is studied. HMB describes menstrual periods with abnormally heavy or prolonged bleeding.
- Trial name
- Champion-HMB (NCT05176496)
- Where
- Germany
- Volunteers
- 99,999 people
- Sponsor
- Bayer